Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Coeptis Therapeutics Holdings Inc COEPW


Primary Symbol: COEP

Healthcare Biotechnology
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health S...


NDAQ:COEP - Post by User

Coeptis Therapeutics Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
  • MasterJediJazz2X
Post by MasterJediJazz2on Feb 19, 2025 11:20am
50 Views
Post# 36459447

$COEP Update out on COEP Venture group

$COEP Update out on COEP Venture group $COEP Update out! "Last week, COEPTIS introduced you to the launch of the COEP Venture Group which will be investing in AI, RPA & AI Agent Startups following the $500B to be invested into U.S Ai infrastructure. Stay with us as we will continue to bring you more exciting updates as we roll out our new vision!" #OpenAi $COEP #COEPVentures #AiNews #Blockchain #Token #Coeptis #Ai #Technology #Aitechnology #MLM #NextGenAl #Biotechnology #celltherapy #cryptonews #NexGenAiAffiliatesNetwork https://x.com/coeptistx/status/1892242626297938378 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities